Robo receptor pathways to block nerve loss in autism-related neurodegeneration
Official title: Robo receptor regulation of neurodegeneration
Funded at Oregon Health & Science University · NIH-11451873 · Data updated 2026-11-12
Aims to find molecular steps that cause nerve fiber and synapse loss in autism-related brain changes and explore how to stop this damage.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project start | August 1, 2026 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $429,000 |
| NIH project number | 1R21NS144983-01A1 |
| Project ID | NIH-11451873 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be adults with autistic disorder who may have biomarkers or models relevant to axon degeneration pathways.
✕Less likely to help
Individuals without autism-related neurodegenerative changes or those not connected to the studied pathways may see no direct benefit.
What this research studies
This project looks at how nerve fibers degenerate after injury and in neurologic conditions linked to autism, focusing on the SARM1 pathway and NMNAT2 in neurons. By studying these molecules in model systems and human context, researchers hope to map new targets to prevent axon and synapse loss. The work combines genetic and molecular approaches to identify steps that trigger degeneration and tests strategies that could preserve neural connections in patients. Findings could point toward therapies that protect brain circuits affected in autistic disorder.
Why it matters
Potential benefit: If successful, this research could reveal new targets to prevent nerve damage and preserve brain connections in people with autism.
How similar studies have gone: Previous work shows the SARM1 pathway is a key driver of axon degeneration in several disease models, suggesting potential for translation.
Where this research is happening
-
Oregon Health & Science University
Portland, United States Active
Researchers
- Principal investigator: Freeman, Marc R — Oregon Health & Science University
- Study coordinator: Freeman, Marc R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.